. 1 Item 1A. Risk Factors . 14 Item 1B. Unresolved Staff Comments . 14 Item 1C. Cybersecurity . 14 Item 2. Properties . 15 Item 3. Legal Proceedings . 15 Item 4. Mine Safety Disclosures . 15 PART II 16 Item 5. Market for Registrants Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities . 16 Item 6. [Reserved] 16 Item 7. Managements Discussion and Analysis of Financial Condition and Results of Operations . 17 Item 7A. Quantitative and Qualitative Disclosures About M...
Q2 FY2026 — expected 2026-08-13
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-31 | 2025-12-31 | 0001104659-26-037933 | EDGAR | 46K words |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-14 | 2025-09-30 | 0001104659-25-111651 | EDGAR | 20K words |
| 2025-10-06 | 2025-06-30 | 0001104659-25-096872 | EDGAR | — |
| 2025-06-02 | 2025-03-31 | 0001410578-25-001388 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-04 | 0001104659-26-023467 | EDGAR | 14K words |
| 2026-02-18 | 0001104659-26-017134 | EDGAR | — |
| 2026-02-09 | 0001104659-26-012016 | EDGAR | — |
| 2026-01-26 | 0001104659-26-006619 | EDGAR | — |
| 2025-11-25 | 0001104659-25-116049 | EDGAR | — |
| 2025-08-25 | 0001104659-25-082579 | EDGAR | — |
| 2025-08-14 | 0001104659-25-078577 | EDGAR | — |
| 2025-07-17 | 0001104659-25-068670 | EDGAR | — |
| 2025-07-11 | 0001104659-25-067444 | EDGAR | — |
| 2025-07-03 | 0001104659-25-065663 | EDGAR | — |
22 total filings indexed. 8 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001971387 |
| Ticker | LIMN |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | http://liminatuspharma.com |
| Listed | 2025-05-01 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report